Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Hormone Receptor-Positive Breast Cancer
Related studies linked through entity extraction aliases.
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
- Status
- RECRUITING
- Phase
- PHASE2
A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
- Status
- RECRUITING
- Phase
- N/A
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Status
- RECRUITING
- Phase
- N/A
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Status
- RECRUITING
- Phase
- N/A
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Status
- RECRUITING
- Phase
- PHASE2
Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient
- Status
- UNKNOWN
- Phase
- NA
VS-6766+Abema+Fulv in Met HR+/HER- BC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
- Status
- SUSPENDED
- Phase
- PHASE3
ETHAN - ET for Male BC
- Status
- RECRUITING
- Phase
- PHASE2
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2